Histone acetylation in reproductive organs: Significance of histone deacetylase inhibitors in gene transcription

Reproductive Medicine and Biology

Volumn 4, Issue 2, 2005, Pages 115-122

  Uchida, Hiroshi ^a   Maruyama, Tetsuo ^a   Arase, Toru ^a   Ono, Masanori ^a   Nagashima, Takashi ^a   Masuda, Hirotaka ^a   Asada, Hironori ^a   Yoshimura, Yasunori ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Histone acetylation; Histone deacetylase inhibitor; Suberoylanilide hydroxamic acid; Trixchostatin A

Indexed keywords

4 N ACETYLDINALINE; APICIDIN; BUTYRIC ACID; ESTROGEN; FR 901228; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; TETRAPEPTIDE; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VALPROMIDE; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BODY WEIGHT DISORDER; BREAST CANCER; BREAST CELL; CANCER INHIBITION; CELL DIFFERENTIATION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; ENDOMETRIOSIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CELL; FEMALE; GENE SILENCING; GENETIC TRANSCRIPTION; GYNECOLOGIC DISEASE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; NONHUMAN; OVARY CANCER; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; WEIGHT GAIN;

EID: 21344445065     PISSN: 14455781     EISSN: 14470578     Source Type: Journal    
DOI: 10.1111/j.1447-0578.2005.00101.x     Document Type: Review

References (53)

1. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997; 389: 251-260.
2. Luger K, Richmond TJ. The histone tails of the nucleosome. Curr Opin Genet Dev 1998; 8: 140-146.
3. Stahl BD, Allie CD. The language of covalent histone modifications. Nature 2000; 403: 41-45.
4. Beyer SL. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 2002; 12: 142-148.
5. Grunstein M. Histone acetylation and chromatin structure and transcription. Nature 1997; 389: 349-352.
6. Gregory PD, Wagner J, Horz W. Histone acetylation and chromatin remodeling. Exp Cell Res 2001; 265: 195-202.
7. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev 2001; 1: 194-202.
8. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-36741.
9. Yamamoto I, Matsunaga T, Sakata K, Nakamura Y, Doi S, Hanmyou F. Histone hyperacetylation plays a role in augmentation of IL-4-induced IgE production in LPS-stimulated murine B-lymphocytes by sodium butyrate. J Biochem (Tokyo) 1996; 119: 1056-1061.
10. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265: 17174-17179
11. Richon VM, Emiliani S, Verdin E et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003-3007.
12. Kelly WK, Richon VM, O'Connor O et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9: 3578-3588.
13. Brinkmann H, Dahler AL, Popa C et al. Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J Biol Chem 2001; 276: 22491-22499.
14. Butler LM, Webb Y, Agus DB et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 2001; 7: 962-970.
15. Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 1999; 18: 2461-2470.
16. Darkin-Rattray SJ, Gurnett AM, Myers RW et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci USA 1996; 93: 13143-13147.
17. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 1993; 268: 22429-22435.
18. Kitazono M, Chuman Y, Aikou T, Fojo T. Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3′, 5′-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86: 834-840.
19. Sandor V, Bakke S, Robey RW et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718-728.
20. Saito A, Yamashita T, Mariko Y et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96: 4592-4597.
21. Kraker AJ, Mizzen CA, Hard BG, Miin J, Allis CD, Merriman RL. Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol Cancer Ther 2003; 2: 401-408.
22. Nemunaitis JJ, Orr D, Eager R et al. Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J 2003; 9: 58-66.
23. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996; 5: 243-253.
24. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92: 1210-1216.
25. Sakai N, Maruyama T, Sakurai R et al. Involvement of histone acetylation in ovarian steroid-induced decidualization of human endometrial stromal cells. J Biol Chem 2003; 278: 16675-16682.
26. Huang L, Sowa Y, Sakai T, Pardee AB. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000; 19: 5712-5719.
27. Finnin MS, Donigian JR, Cohen A et al. Structures of a histone deacetylase homologue bound to TSA and SAHA. Nature 1999; 401: 188-193..
28. Strait KA, Dabbas B, Hammond EH et al. Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 2002; 1: 1181-1190.
29. Takai N, Desmond JC, Kumagai T et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004; 10: 1141-1149.
30. Han JW, Ahn SH, Kim YK et al. Activation of p21 (WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J Biol Chem 2001; 276: 42084-42090.
31. Kim YK, Han JW, Woo YN et al. Expression of p21 (WAF1/Cip1) through Sp1 sites by histone deacetylase inhibitor apicidin requires PI3-kinase-PKC epsilon signaling pathway. Oncogene 2003; 22: 6023-6031.
32. Fu Y, Campbell EJ, Shepherd TG, Machtigal MW. Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol Cancer Res 2003; 1: 569-576.
33. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin A (TSA) and SAHA. J Biol Chem 2003; 278: 12579-12589.
34. Reuben RC, Wife RL, Breslow R, Rifkind RA, Marks PA. A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc Natl Acad Sci USA 1976; 73: 862-866.
35. Munster PN, Troso-Sandoval T, Rosen N et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001; 61: 8492-8497.
36. Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol 2004; 16: 14-23.
37. Kitazono M, Goldsmith ME, Aikou T, Bates S, Fojo T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res 2001; 61: 6328-6330.
38. Lim Y, Han I, Kwon HJ, Oh ES. Trichostatin A-induced detransformation correlates with decreased focal adhesion kinase phosphorylation at tyrosine 861 in ras-transformed fibroblasts. J Biol Chem 2002; 277: 12735-12740.
39. Dehm SM, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol 2004; 82: 263-274.
40. Rombouts K, Knittel T, Machesky L et al. Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. J Hepatol 2002; 37: 788-796.
41. Kim MS, Kwon HJ, Lee YM et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-443.
42. Williams RJ. Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin Invest Drugs 2001; 10: 1571-1573.
43. Rossig L, Li H, Fisslthaler B et al. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 2002; 91: 837-844.
44. Mie Lee Y, Kim SH, Kim HS et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor via suppression of HIF-1α, activity. Biochem Biophys Res Commun 2003; 300: 241-246.
45. Talukder AH, Mishra SK, Mandal M et al. MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions. J Biol Chem 2003; 278: 11676-11685.
46. Sun JM, Chen HY, Davie JR. Effect of estradiol on histone acetylation dynamics in human breast cancer cells. J Biol Chem 2001; 276: 49435-49442.
47. Jang ER, Lim SJ, Lee ES et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 2004; 23: 1724-1736.
48. Margueron R, Licznar A, Lazennec G, Vignon F, Cavailles V. Oestrogen receptor alpha increases p21 (WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol 2003; 179: 41-53.
49. Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrin 2004; 145: 799-808.
50. Kim JM, Liu H, Tazaki M, Nagata M, Aoki F. Changes in histone acetylation during mouse oocyte meiosis. J Cell Biol 2003; 162: 37-46.
51. Fenic I, Sonnack V, Failing K, Bergmann M, Steger K. In vivo effects of histone-deacetylase inhibitor trichostatin A on murine spermatogenesis. J Androl 2004; 25: 811-818.
52. Nervi C, Borello U, Fazi F, Buffa V, Pelicci PG, Cossu G. Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. Cancer Res 2001; 61: 1247-1249.
53. Condon JC, Jeyasuria P, Faust JM, Wilson JW, Mendelson CR. A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. Proc Natl Acad Sci USA 2003; 100: 9518-9523.